We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Meanwhile, after unveiling its own cardiovascular outcomes data at ADA, rival Johnson & Johnson will have subanalyses of its own to present later in the week.
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.